Cutting-edge innovation will help fuel better cancer care, today and tomorrow. The Research and Development team at Foundation Medicine is relentless in that pursuit of a richer science. Leveraging scientific insights through software, we help transform cancer care with one significant advantage: access to one of the largest genomic databases in the world.
Rediscover your curiosity and passion for life-changing science with us.
Dr. Hegde joined Foundation Medicine as the Chief Scientific Officer in August 2019. Her team comprises of Cancer Genomics, Research and Early Development, Computational Biology, Translational Strategy, Franchise Development, and Product Development (inclusive of Assay Development, Companion Diagnostic Development Operations, Regulatory, and Biomarkers and Biometrics).
Dr. Hegde has spent nearly two decades in the biopharmaceutical industry, with a proven track record in drug development, registration, and commercialization of therapeutics with companion diagnostics in cancer immunotherapy.
Current Open Roles on the Team:
|Senior Scientist, Companion Diagnostics||Development Operations||100710||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||About the Job The Senior Scientist, Companion Diagnostics sits on the Companion Diagnostics (CDx) Development Operations Team and is responsible for developing companion diagnostics and for contributing to the regulatory strategy of new NGS-based...|
|Scientist II, Molecular Biology & Sequencing||Research and Early Development||100707||San Diego||California||United States||Towne Centre Ct., San Diego, California, United States||R&D||About the Job Scientist II, Molecular Biology & Sequencing is part of the Research and Development Team in FMI’s Early Research team. The primary role of this position is to explore new technologies and biomarker candidates with the focus to ...|
|Computational Biologist||Cancer Genomics||100631||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||About the Job The Computational Biologist on the Cancer Genomics team investigates computational, bioinformatic and statistical aspects of genomic and epigenomic data as part of multidisciplinary teams developing new technologies and approaches t...|
|Scientist I Computational Biologist||Computational Biology||100492||Boston||Massachusetts||United States||Seaport Blvd., Boston, Massachusetts, United States||R&D||Key Responsibilities • Work within an interdisciplinary team of molecular biologists, computational biologists, and software engineers focused on developing diagnostic products using massively parallel sequencing of tumor genomic DNA and RNA. • ...|
|Associate Director, Franchise Development||Franchise Development||100482||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||About the Job The Associate Director, Franchise Development helps to lead the strategy and implementation of a designated product or portion of the clinical product portfolio. The position is responsible for directing the strategy, ideation, rele...|
|Manager Regulatory Affairs||Regulatory||100628||San Diego||California||United States||Towne Centre Ct., San Diego, California, United States||R&D||About the Job The Manager, Regulatory Affairs is responsible for supporting the regulatory function and its activities, the development of regulatory strategy, and contributing the regulatory approval process (including US FDA and other regulator...|
|Scientist I, Companion Diagnostics||Development Operations||100725||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||About the Job The Scientist I, Companion Diagnostics (CDx) role supports the full product development lifecycle, from concept through commercial launch, of new Next Generation Sequencing (NGS)-based assays under 21 CFR part 820 Quality System Reg...|
|Scientist I, Research & Early Development||Research and Early Development||100775||San Diego||California||United States||Towne Centre Ct., San Diego, California, United States||R&D||About the Job The Scientist I role is part of the Research and Early Development team in FMI’s Product Development group. This position explores new technologies and biomarker candidates to address unmet needs in the oncology field. The position ...|
|Principal Scientist Computational Biology||Computational Biology||100394||Boston||Massachusetts||United States||Seaport Blvd., Boston, Massachusetts, United States||R&D||Key Responsibilities • Integrate clinical DNA-seq and RNA-seq diagnostic assays into a unified platform that supports FMI’s product portfolio expansion, in close collaboration with a multidisciplinary team of scientists, engineers and computation...|
|Scientist II, Assay Development||Assay Development||100751||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||About the Job The Scientist II, Assay Development supports the late-stage development and optimization of next generation sequencing (NGS) based assays in our clinical labs. Leveraging strong working knowledge of molecular biology, the incumbent ...|
|Associate Director, Biomarker Analysis||Biomarkers and Biometrics||100729||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||Key Responsibilities • Manage and lead the Biomarker Team’s day-to-day workflow. • Lead the design and analysis of novel NGS-based biomarkers for precision medicine. • Lead the novel biomarker development. • Lead efforts to improve the consist...|
|Senior Manager, Regulatory Affairs (Data Products)||Regulatory||100781||Cambridge||Massachusetts||United States||Second Street, Cambridge, Massachusetts, United States||R&D||About the Job The Senior Manager, Regulatory Affairs is responsible for supporting the regulatory function and its activities, the development of regulatory strategy, and contributing the regulatory approval process for FMI data products or platf...|
FoundationOne CDx was recently approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel.
Learn more on our blog about how this approval demonstrates the power of cancer precision medicine in action and the role that comprehensive genomic profiling plays.
- Garrett Frampton, PhD, Sr. Director, Cancer Genomics
We are thrilled to announce the FDA approval of FoundationOne®Liquid CDx, FMI’s comprehensive liquid biopsy test, for all solid tumors. This approval is such an important milestone because we can now offer oncologists multiple FDA-approved, high-quality comprehensive genomic profiling options. From a simple blood draw, FoundationOne Liquid CDx can provide physicians and patients with molecular insights to inform treatment decisions whether that be targeted therapies, clinical trials or immunotherapy.
For more about this approval, click here to read the press release.
The Best of the AACR Journals collection highlights the most-cited articles published in 2018 across the AACR journals. Congratulations to our Director of Cancer Genomics Research, Lee A. Albacker for his most-cited article entitled STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Enter your details and we will notify you when new roles that might be a fit are posted!